Sparrow Pharma
Portland, US · Founded 2013 · Delaware corporation · 17 employees on LinkedIn · 4 known investors
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
Founders & leadership
RJ
Robert JacksExecutive
DA
David Aaron KatzNamed on SEC filing
Board
JR
NO
ZS
KV
NL
Nanna L?neborgBoard director
PT
Investors · 4
Reported raises · per SEC filings
Form D private placements$73.3M disclosed across 4 rounds · 2018–2025
▶$61.8MraisedJul 2025 · 17 investors · PharmaceuticalsRule 506(b)
▶$61.8MraisedJul 2025 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan RootDirector
- Niall O'DonnellDirector
- Zach ScheinerDirector
- Klaus VeitingerDirector
- Nanna L?neborgDirector
- Peter ThompsonDirector
- Robert JacksExecutive Officer, Director
- Offering amount
- $121.4M
- Amount sold
- $61.8M
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedApr 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$10MraisedApr 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter ThompsonDirector
- Jonathan RootDirector
- Klaus VeitingerDirector
- Niall O'DonnellDirector
- Robert JacksExecutive Officer, Director
- Offering amount
- $15.3M
- Amount sold
- $10M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedJan 2021 · 15 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedJan 2021 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David KatzExecutive Officer
- Robert JacksExecutive Officer, Director
- Peter ThompsonDirector
- Klaus VeitingerDirector
- Offering amount
- $50.8M
- Amount sold
- $1.1M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$337.5KraisedJun 2020 · 10 investors · PharmaceuticalsRule 506(b)
▶$337.5KraisedJun 2020 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David Aaron KatzExecutive Officer, Director
- Offering amount
- $337.5K
- Amount sold
- $337.5K
- Minimum investment
- $10K
- Sales commissions
- $675
- Placement agents
- Exemplar Capital, LLC
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAro Biotherapeutics13 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Spero Therapeutics13 shared keywordsSpero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease. It focuses on immune signaling pathways involved in inflammation and fibrosis, with potential applications across additional immune-mediated conditions.
Companies competing with Sparrow Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Sparrow Pharma do?
- Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease. Its lead program, clofutriben, is an HSD-1 inhibitor being evaluated in a Phase 2b trial for patients with inadequately controlled type 2 diabetes driven by elevated cortisol.
- Who are Sparrow Pharma's investors?
- Sparrow Pharma's investors include OrbiMed, RA Capital, RiverVest Venture Partners, US Venture Partners.
- How much funding has Sparrow Pharma raised?
- Sparrow Pharma has disclosed $73.3M raised across 4 rounds.
- Where is Sparrow Pharma headquartered?
- Sparrow Pharma is headquartered in Portland, US.